Clinical Trials Directory
We created this registry for people with rare breast tumors to help us learn more about them and how to better treat people in the future.
We are doing this study to find out if an experimental drug called ravulizumab (the study drug) is a safe and effective option to prevent or reduce the severity of delayed graft function after people with end-stage kidney disease (ESKD) get a kidney transplant.
This study lasts for about one and a half months. People will go to the doctor up to six times in person and have one phone call visit. The first visit will take about four and a half hours and will include a brain scan and tests to see how well someone can do certain tasks. This long visit can be split into two shorter visits if that is easier. After that, there will be three visits where people get a special kind of treatment, and each of those visits will take about an hour and a half.
We are doing this study to find out if the experimental combination of the drugs finalimab and cemiplimab (the study drugs) is a safe and effective option for people with high-risk melanoma. We want to see how well the study drugs work compared to treatment with pembrolizumab.
We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.
We are doing this study to find out if an experimental study drug called RP1 (the study drug) is a safe and effective option for people who have advanced melanoma. We want to know how the study drug works when it is combined with a cancer drug called nivolumab in comparison to several other standard treatments for advanced melanoma (nivolumab + relatlimab OR nivolumab alone OR pembrolizumab alone).
We are doing this study to find out if an experimental drug called RP2 (the study drug) is a safe and effective option for people who have uveal melanoma (melanoma in the eye). We want to know how well the study drug works when it is combined with a drug called nivolumab, and we will compare its outcomes to treatment with the drug combination of nivolumab + ipilimumab.